Diagnosing Alzheimer's earlier rather than later

May 9, 2016, Ecole Polytechnique Federale de Lausanne
Targeting early seeds of Abeta oligomerization” Credit: Felix Rehsteiner (Carapaz SA)

A hallmark of Alzheimer's disease is the appearance of plaques in the brain. The plaques are gradually made up by the aggregation of a small protein called amyloid-beta or "Abeta". Alzheimer's is usually diagnosed late, when the plaques have developed and are already causing cognitive damage like memory loss. In a large study led by EPFL, an international team of scientists from Harvard, Edinburgh and Ulm, have now found a way to detect Abeta aggregation in its early stages, which will make diagnosing and treating the disease much more effective. The study is published in the journal Alzheimer's and Dementia.

Alzheimer's – and a number of other diseases – begins when Abeta proteins begin to aggregate, or clump together, in the brain and form larger structures called oligomers ("oligo" = few). The oligomers themselves then clump together to form the even larger amyloid plaques. The problem is that the molecular mechanisms that lead single Abeta to clump into oligomers early on are not well studied, and even the exact structure of the oligomers is a matter of debate among scientists.

Scientists at EPFL's Protein Core Facility, have now led an international team of scientists from Harvard, Edinburgh and Ulm in one of the most extensive analysis of Abeta peptides. The project aimed to understand what happens during aggregation, and particularly at its early stages.

Using different analysis techniques (e.g. mass spectrometry), the researchers identified specific points on Abeta where it undergoes a process called "autocleavage". Normally, Abeta is cut by specialized enzymes as part of the cell's cleaning process. But, in this case, Abeta simply breaks at very specific points along its structure without any enzymes being involved.

The researchers found that Abeta autocleavage happens during the early stages of aggregation. The process generates truncated Abeta fragments, which can then form complexes with normal, unbroken Abeta molecules. This produces the neurotoxic oligomers that are thought to cause the early cognitive problems of Alzheimer's.

In addition, the scientists found that autocleavage of Abeta also produces a pattern or "fragment signature" that is highly reproducible, meaning that it can be used to detect Abeta aggregation early on.

The research team also screened mice that are used as standard models of Alzheimer's disease, as well as human post-mortem brain tissue and cerebrospinal fluid. The investigation showed that the process of autocleavage, (as a result of Abeta aggregation), is a highly relevant clinical feature of Alzheimer's.

Finally, the researchers also found that the truncated peptides can be used to develop antibodies that can identify and bind them. This would enable doctors to monitor the accumulation of truncated Abeta fragments in diagnostic tools, and even target them for clearing by the patient's immune system.

"The study reveals novel Abeta targets associated with the early events of oligomerization," says Adrian Schmid at EPFL's Protein Core Facility and senior author of the paper. "This may help define the preclinical stage of Alzheimer's, and determine the factors that predict the emergence of clinical impairment and progression to severe dementia."

The findings take our knowledge about Abeta to a new level and have important implications in Alzheimer's diagnosis and future therapies. "Preclinical biomarkers of dementia can help identify individuals who may benefit from early therapeutic intervention," says Schmid. "It can therefore improve the patient's overall quality of life while reducing the costs associated with long-term medical care."

Explore further: An implant to prevent Alzheimer's

More information: Nikita Rudinskiy et al. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint, Alzheimer's & Dementia (2016). DOI: 10.1016/j.jalz.2016.03.011

Related Stories

An implant to prevent Alzheimer's

March 17, 2016
In a cutting-edge treatment for Alzheimer's disease, EPFL scientists have developed an implantable capsule that can turn the patient's immune system against the disease.

Study challenges scientific principle about Alzheimer protein amyloid beta

October 14, 2015
Scientific Reports, a Nature group journal, has recently published results that challenge the findings of studies to date on the initial aggregates formed by amyloid beta, a protein closely associated with the onset and development ...

Alzheimer's culprit causes memory loss even before brain degeneration

May 29, 2015
The study, published May 29 in the open access Nature Publishing Group journal Scientific Reports, reveals a direct link between the main culprit of Alzheimer's disease and memory loss.

Finding ways to detect and treat Alzheimer's disease

February 17, 2014
Alzheimer's disease has long been marked by progress—but not the kind of progress the medical community seeks. It is the most common form of dementia among older Americans, and its risk increases with increasing age; for ...

Right target, but missing the bulls-eye for Alzheimer's

January 24, 2013
(Medical Xpress)—Alzheimer's disease is the most common cause of late-life dementia. The disorder is thought to be caused by a protein known as amyloid-beta, or Abeta, which clumps together in the brain, forming plaques ...

Recommended for you

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...

Massive study confirms that loneliness increases risk of dementia

October 29, 2018
A new Florida State University College of Medicine study involving data from 12,000 participants collected over 10 years confirms the heavy toll that loneliness can take on your health: It increases your risk of dementia ...

Bioactive compound from the Rhodiola plant improves memory

October 25, 2018
In an ageing society, more people are suffering from memory disorders. The progressive loss of memory severely impairs the quality of life of those affected. So far, no drugs are known to prevent age-related cognitive decline.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.